Association of non-HDL-C-to-HDL-C ratio with coronary lesions and its prognostic performance in first-onset NSTEMI

Area of Science:

• Cardiology
• Lipid Metabolism
• Cardiovascular Disease

Background:

• Acute myocardial infarction (AMI) poses a significant cardiovascular risk.
• Non-ST-segment elevation AMI (NSTEMI) requires effective risk stratification.
• The NON-HDL-C:HDL-C ratio is an emerging marker for cardiovascular risk.

Purpose of the Study:

• To evaluate the association of the NON-HDL-C:HDL-C ratio with coronary lesions.
• To determine the predictive value of the NON-HDL-C:HDL-C ratio for major adverse cardiovascular events (MACE) in first-onset NSTEMI.
• To assess the diagnostic performance of the NON-HDL-C:HDL-C ratio for cardiovascular risk factors.

Main Methods:

• A cohort of 426 patients with first-onset NSTEMI undergoing early invasive therapy was analyzed.
• Major adverse cardiovascular events (MACE) were defined as cardiac death, nonfatal myocardial infarction, target vessel revascularization, congestive heart failure, and nonfatal stroke.
• Statistical analyses were performed to assess the association and predictive value of the NON-HDL-C:HDL-C ratio.

Main Results:

• The NON-HDL-C:HDL-C ratio demonstrated strong diagnostic performance for multiple cardiovascular risk factors (p < 0.05).
• This ratio independently predicted severe coronary lesions and MACE in NSTEMI patients (p < 0.05).
• Subgroup analyses confirmed the ratio's robustness, particularly in elderly, male, dyslipidemic, or nondiabetic individuals.

Conclusions:

• The NON-HDL-C:HDL-C ratio is significantly associated with the presence of coronary lesions in NSTEMI.
• This lipid ratio serves as an independent predictor of MACE, offering prognostic value in NSTEMI patients.
• The NON-HDL-C:HDL-C ratio is a valuable tool for risk assessment and prognosis in NSTEMI management.